CareDx Inc
$ 21.42
-4.46%
17 Apr - close price
- Market Cap 1,101,687,000 USD
- Current Price $ 21.42
- High / Low $ 23.24 / 20.90
- Stock P/E N/A
- Book Value 5.95
- EPS -0.40
- Next Earning Report 2026-04-28
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.03 %
- ROE -0.06 %
- 52 Week High 23.24
- 52 Week Low 10.96
About
CareDx, Inc. discovers, develops and markets diagnostic solutions for transplant patients and caregivers globally. The company is headquartered in South San Francisco, California.
Analyst Target Price
$24.80
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-28 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.04 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CDNA
2026-04-17 09:39:48
Sumitomo Mitsui Trust Group Inc. reduced its stake in CareDx, Inc. by 16.9% in the fourth quarter, selling 293,448 shares and now holding 1,446,616 shares valued at $27.25 million. CareDx missed its Q4 EPS consensus despite revenue growth, reporting a negative net margin and ROE. The company currently holds a "Hold" consensus rating from analysts with an average target price of $27.60.
2026-04-17 07:39:48
CareDx has announced the sale of its Lab Products business to EuroBio Scientific for $170 million, allowing it to focus on its higher-growth precision testing and digital solutions. This strategic move aims to simplify operations and improve capital allocation, with proceeds supporting long-term growth initiatives and potential acquisitions. Preliminary first-quarter 2026 results show strong revenue growth for CareDx's core services, despite a decline in Lab Products revenue.
2026-04-17 00:10:14
CareDx Inc (CDNA) shares surged 27.6% to $22.42, marking it as "Modestly Overvalued" according to GuruFocus, with a GF Value™ of $18.98. Despite a strong GF Score™ of 80/100, indicating good financial strength and growth, its profitability is low, and insiders have sold $0.5 million worth of stock recently, raising caution for investors. The current P/E ratio of 32.1x is also significantly higher than its 5-year median, further suggesting overvaluation.
2026-04-16 20:10:15
CareDx, Inc.'s President and CEO, John Walter Hanna Jr., had 62,049 shares of common stock withheld by the company at $17.57 per share to cover tax obligations upon the vesting of restricted stock units. This was a routine tax-related share disposition, and after this transaction, he still holds 686,757 common shares directly, maintaining a substantial equity position. The transaction, classified as a tax-withholding disposition, was detailed in an SEC Form 4 filing on April 16, 2026.
2026-04-16 19:39:07
CareDx (CDNA) shares are up 28% and are on track to record their largest percentage increase since May 2024. This significant rise highlights a positive market reaction, potentially influenced by recent data or company performance.
2026-04-16 18:10:14
CareDx has announced the sale of its Lab Products business to EuroBio Scientific for $170 million, allowing it to concentrate on its core Testing Services and Patient and Digital Solutions. This strategic move aims to simplify operations, improve capital allocation, and support long-term growth initiatives. The company reported strong preliminary first-quarter 2026 revenue, with significant growth in its core service areas.
